When to Restart Eliquis After Bursectomy
Restart apixaban (Eliquis) at least 24 hours after bursectomy once adequate hemostasis has been established. 1
Timing Based on Bleeding Risk
Bursectomy is typically a low-to-moderate bleeding risk procedure (minor orthopedic surgery with easily controllable bleeding). For such procedures:
- Resume apixaban ≥24 hours post-procedure 2, 1
- The FDA label explicitly states: "ELIQUIS should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established" 1
- For low-bleeding-risk procedures, the 2022 ACCP guidelines recommend waiting at least 24 hours before resuming therapeutic anticoagulation 2
Key Clinical Considerations
Verify adequate hemostasis before restarting:
- No active bleeding from surgical site
- Stable vital signs
- No expanding hematoma
- Surgical drain output (if present) is minimal and non-bloody
If higher bleeding risk exists (e.g., extensive dissection, poor hemostasis, patient on antiplatelet agents):
- Consider delaying restart to 48-72 hours post-procedure 2
- This approach reduced major bleeding to <5% in observational studies of high-bleed-risk surgeries 2
Dosing Upon Restart
Resume the full therapeutic dose that the patient was taking pre-operatively:
- Most patients: 5 mg twice daily
- Dose-reduced patients (age ≥80, weight ≤60 kg, or creatinine ≥1.5 mg/dL): 2.5 mg twice daily 1
Do not use a "loading dose" or altered regimen when restarting—simply resume the regular maintenance dose 1.
Common Pitfalls to Avoid
- Don't restart too early (<24 hours): Studies show major bleeding rates of 20% when therapeutic anticoagulation was started 12-24 hours after major surgery 2
- Don't bridge with heparin: Bridging during the 24-48 hour interruption period is not generally required for apixaban 1
- Don't skip the hemostasis check: Even at 24+ hours, only restart if bleeding has completely stopped 3
- Don't confuse prophylactic with therapeutic dosing: The 2.5 mg twice daily dose used for post-surgical VTE prophylaxis (hip/knee replacement) is different from therapeutic anticoagulation dosing 1
Supporting Evidence
The 2022 ACCP guidelines (highest quality available) recommend waiting ≥24 hours for low-moderate bleeding risk procedures, with flexibility to extend to 48-72 hours for higher-risk situations 2. The European Heart Rhythm Association 2018 guidelines align with this approach, recommending resumption 24 hours post-low-bleeding-risk interventions 3. Real-world data from bariatric surgery (a moderate bleeding risk procedure) shows safe apixaban initiation at 72 hours post-operatively with minimal bleeding complications 4, 5.